Currently Javascript deactivated in your browser.
Search

GlaxoSmithKline

By Dolat Capital 

Monday, November 26, 2012
     

Dolat Capital is bullish on GlaxoSmithKline Pharma and has recommended accumulate rating on the stock with a target of Rs 2104 in its November 21, 2012 research report.

GlaxoSmithKline (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, including human immunodeficiency virus (HIV), central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, vaccines and dermatologicals. The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. It has global manufacturing and research and development presence. On January 31, 2012, the Company completed the divestment of brands in the United States and Canada to Prestige Brands Holdings. In August 2012, it acquired Human Genome Sciences.

The report says, "GSK Pharma, Topline grew 10 percent YoY to Rs 6.68bn. During the quarter Pharma segment’s revenue grew 11% YoY. Revenue impact due to constraints in sterile manufacturing owing to shutdown of one of the suppliers (quality issues) and constraints at the Nashik facility was about 2 percent. These issues have been resolved. The company continues to perform well in specialties and vaccines", as quoted by Moneycontrol.